Author: Dr Chin-Yun Lin, Dermatology Registrar, Waikato Hospital, Hamilton, New Zealand, 2012.
Intralesional steroid injection involves a corticosteroid, such as triamcinolone acetonide or betamethasone suspension, which is injected directly into a lesion on or immediately below the skin.
In New Zealand triamcinolone is marketed as Kenacort-A, and is available in 2 strengths: 10 mg per ml (Kenacort-A 10), or 40 mg per ml (Kenacort-A 40). Triamcinolone acetonide is marketed as Kenalog in the USA. Betamethasone injection is marketed as Celestone Chronodose (1 mL).
Shorter-acting corticosteroid preparations, such as dexamethasone or betamethasone acetate, are sometimes administered in combination with triamcinolone.
Intralesional steroid injection may be indicated for the following skin conditions:
Intralesional administration of corticosteroids is used to treat a dermal inflammatory process directly. In contrast to topical steroids, intralesional steroids:
Triamcinolone is also sometimes used intramuscularly as an alternative to oral corticosteroids, for example for seasonal hay fever, or to treat a chronic skin disorder such as atopic dermatitis or lichen planus.
Typical intramuscular doses are 0.5–1 mg/kg body weight (40-80 mg for typical adult), which may be repeated every 30 days for 3 to 6 months.
Triamcinolone injections can also be used in the treatment of tendonitis, arthritis and synovitis.
They must not be used if there is a previous history of triamcinolone hypersensitivity (allergy).
When large doses of triamcinolone acetonide injections are used as an alternative to oral steroids such as prednisone, they are considered to be systemic steroids. These should be avoided in patients with the following disorders.
Intralesional triamcinolone is injected directly into the skin lesion using a fine needle after cleaning the site of injection with alcohol or antiseptic solution. The injection should be intradermal, not subcutaneous, to avoid causing a dent in the skin.
The initial dose per injection site will vary depending on the lesion being treated. Generally, 0.1–0.2 mL is injected per square centimetre of involved skin. The total dose should not normally exceed 1 or 2 mL per dose. It can be repeated every 4 to 8 weeks.
The corticosteroid can be full strength (eg triamcinolone 10 mg/mL or 40 mg/mL) or diluted with normal saline or local anaesthetic. Typical regimes for triamcinolone intralesional injections include:
The injections may be repeated monthly for a few months while the lesions are active.
Side effects and risks of intralesional triamcinolone may be separated into early and delayed effects.
Early effects tend to be self-limited. They include:
Delayed adverse effects include:
Allergic reactions are very rare, and dose independent but may include local or generalised urticaria (wheal and flare), and in more severe cases, anaphylaxis (angioedema, swollen face/tongue, respiratory distress, hypotension/shock).
Other systemic side-effects are not likely to follow intralesional injection of localised skin disease because the dose used is very small.
However, the following potentially serious conditions have been reported from intramuscular injection of large doses of triamcinolone acetonide.
See the DermNet NZ bookstore
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.